# Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers

> **NCT05860530** · NA · COMPLETED · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** The test olaparib tablet (T)
- **DRUG:** The reference olaparib tablet (R)

## Key facts

- **NCT ID:** NCT05860530
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-10
- **Primary completion:** 2021-09-08
- **Final completion:** 2021-09-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05860530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05860530, "Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05860530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*